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Human granulocytes i olated from peripheral blood have been described to synthesize both LTB4 and 
LTC4 from arachidonic acid. We have observed that the amount of LTC4 produced by human granulocyte 
preparations i strongly dependent on the relative amount of eosmophils. To investigate a possibly 
significant difference in leukotriene synthesis of the eosinophilic and neutrophilic granulocytes, we 
developed a purification method to isolate both cell types from granulocytes obtained from the blood of 
healthy donors. Leukotrlenes were generated by incubation of the purified cells with arachidonic acid, 
calcium lonophore A23187, calcium-chlonde and reduced glutatbione. Surprisingly, eosinophils were 
found to produce almost exclusively the spasmogenic LTC4. In contrast, neutropbils produce almost 
exclusively the chemotactic LT&, its w-hydroxylated metabolite 20-hydroxy-LTB4 and two non- 
enzymically formed LTB4 isomers. 
Leukotnene Granulocyte Eosmophil 
1. INTRODUCTION 
Leukotrienes constitute an important class of 
biologically active arachidonic acid metabolites, 
formed via the lipoxygenase pathway. Several 
types of human blood and tissue cell e.g., granulo- 
cytes [1,2], lymphocytes [3], macrophages [4,5] 
and mast cells [6], are capable of synthesizing leu- 
kotrienes from arachidonic acid. Leukotriene C4 
(LTC4: S(S)-hydroxy-6(R)-S-glutathionyl-7,9trans- 
11,14-cis-eicosatetraenoic acid) and leukotriene D4 
(LTD4: 5(S)-hydroxy-6(R)-Scysteinylglycyl-7,9- 
trans- 11,14-cl,.+eicosatetraenoic acid) have been 
shown to be strongly bronchoconstrictive in vitro 
[7] as well as in vivo [S] and therefore may play an 
important role as mediators in (immediate) hyper- 
sensitivity reactions. Leukotriene B4 (LTB4: 5(s), 
Neutrophrl Llpoxygenase Asthma 
12(R)-dihydroxy-6,14-cis-8,lO&anseicosatetrae- 
noic acid) possesses a pronounced chemotactic ac- 
tivity for human neutrophils [9] and eosinophils 
[lo]. Since eosinophils probably play an important 
role in hypersensitivity reactions, it is of interest o 
know whether these cells are capable of producing 
leukotrienes and if so whether the leukotriene for- 
mation by eosinophils differs qualitatively and/or 
quantitatively from the formation of leukotrienes 
by neutrophils. 
Recently the production of leukotrienes by 
purified horse eosinophils [ 111, murine eosinophils 
[ 121 and human eosinophils [ 13,141 has been 
described. Authors in [12,13] observed that murine 
and human eosinophils produce leukotrienes of the 
5- and 15-series in almost equal amounts. Authors 
in [l l] reported that horse eosinophils produce 
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LTB4 and LTB4 isomers as well as about 4-times as 
much sulfidopeptide leukotrienes per cell as horse 
neutrophils. Authors in [14] found that - in the 
absence of added glutathione - human eosino- 
phils produce small amounts of LTB4, LTC4 and 
LTD4. 
So far, leukotriene formation by human eosino- 
phils and neutrophils under optimal conditions has 
not been compared in detail. 
Here, a method has been developed to purify 
human eosinophils and neutrophils from granulo- 
cyte preparations obtained from quantities as 
small as 100 ml blood from healthy donors. The 
formation of leukotrienes by eosinophils and 
neutrophils has been compared in the presence of 
sufficient amounts of glutathione to enable op- 
timal production of sulfidopeptide leukotrienes. 
2. MATERIALS AND METHODS 
2.1. Materials 
Arachidonic acid (purity > 99Oi’o) was purchased 
from Fluka (Buchs, Switzerland) and Nu Chek 
Prep, Inc. (MN). Calcium ionophore A23187, 
reduced glutathione, PGBz and 4-hydroxy-2,2,6,6- 
tetramethylpiperidinooxy free radical were from 
Sigma (St. Louis, MO). Percoll (1.129 g/ml) and 
Ficoll-Paque (1.077 g/ml) were obtained from 
Pharmacia (Uppsala). Solvents, which were all of 
HPLC quality, and octadecyl reversed-phase x- 
traction columns (6 ml) were purchased from 
Baker (Deventer, The Netherlands). Synthetic 
LTB4, LTG and LTD4 were a kind gift of Dr J. 
Rokach (Merck-Frosst Laboratories, Pointe 
Claire/Dorval, Quebec). Human blood was ob- 
tained from healthy volunteers of the Red Cross 
Bloodbank Foundation (Utrecht). 
2.2. Purrfication of granulocytes 
Granulocytes were isolated as follows: platelet- 
rich plasma was removed after centrifugation of 
- 
titrated blood at 275 x g for 15 min. After collec- 
tion of the buffy coat, granulocytes were separated 
from lymphocytes and monocytes by centrifuga- 
tion on Ficoll-Paque at 650 x g for 20 min. The 
remaining erythrocytes were removed by 
ammonium-chloride lysis at 0°C and subsequent 
centrifugation. 
The purity of the cell preparations was found to 
be better than 97%. The content of eosinophils in 
these preparations ranged from 2 to 8%. 
2.3. Purification of eosinophils and neutrophils 
Eosinophils and neutrophils were separated 
from each other by two subsequent centrifugations 
of a granulocyte preparation in isotonic Percoll 
solutions with densities of 1.085 and 1.088 g/ml at 
1000 x g for 10 min at room temperature. 96 f 3% 
pure neutrophils appeared at the top of the 1.085 
g/ml Percoll solution, while the eosinophils and 
some neutrophils were present as a small pellet on 
the bottom. 
After resuspension of the eosinophil pellet in a 
1.088 g/ml Percoll solution and centrifugation at 
1000 x g for 10 min at room temperature, 96 + 4% 
pure eosinophils appeared on the bottom of the 
tube. 
Recoveries were 37+ 16% and 85+ 10% for 
eosinophils and neutrophils, respectively (n = 5). 
Cell integrity was measured with the vital stains 
fluorescein diacetate and ethidium bromide 
[ 15,161. Further support for cell integrity was ob- 
tained by the absence of lactate dehydrogenase and 
fl-glucuronidase activities in the supernatants of 
isolated, unstimulated cells. 
2.4. Incubation procedure 
Eosinophils or neutrophils were suspended in 
Dulbecco’s salt solution (pH 7.4) at a concentra- 
tion of approx. 10’ cells/ml, preincubated at 37°C 
for 5 min and then incubated at 37’C for 5 min 
with 80 PM arachidonic acid, 20 pM calcium iono- 
phore A23187, 1 mM (extra) CaCl2 and 5 mM 
Fig. 1. RP-HPLC chromatograms of the leukotrrenes produced from arachidomc acid (80 /IM) by 8 x lo6 neutrophrls 
(purity 99Vo) or eosmophils (purity 98Qlo) isolated from the same granulocyte preparation. Solvent system: 
tetrahydrofuran-methanol-water-acetic a id (25:30:45:0.1, by vol.), pH 5.5, flow rate: 0.9 ml/mm. UV spectra were 
recorded of all peaks. Synthetic LTB4 abd LTG were used as references. Identification of peaks: 1, 24%hydroxy-LTB4; 
2, LTG; 3, lit-LTC4; 4, L?epr,6t-LTB4 + 6f-LTB4; 5, LTB4; 6, 12epi,61,8c-LTB4 (double-dloxygenation product). X, 
15-series leukotrienes. NB, the peak m the eosmophil chromatogram having a position almost identical with the 
20-hydroxy-LTB4 peak in the neutrophil chromatogram does not possess a characteristic trrene UV spectrum. 
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reduced glutat~one. Reactions were stopped by 
the addition of ice to the incubation mixture. 
2.5. Sample preparatmn 
The incubation mixture was centrifuged at 
46 000 x g for 10 min at 4°C. For the extraction 
of the formed leukotrienes octadecyl (C18) 
reversed-phase xtraction columns (6 ml) were 
used, which were first washed with methanol and 
water, respectively, according to the manufac- 
turers instructions. After applying the cell superna- 
tant (pH 7.4) to the column and washing with 
water, the absorbed leukotrienes were eluted with 
methanol (usually 3 m1). Recovery for al1 leuko- 
trienes was found to be better than 85%. 
After addition of the radical scavenger 
4-hydroxy-2,2,6,6-tetramethylpiperidinooxy free 
radical (2 pg/3 ml), the eluates were stored under 
nitrogen at -70°C until they were analyzed by 
RP-HPLC. 
2.6. Reversed-phase high-performance liquid 
chromatography (RP-HPLCJ 
Leukotrienes were separated and quantified, as 
in [17] by isocratic RP-HPLC, using a Nucleosil 
5C18 column (250 x 4.6 mm, Chrompack, Mid- 
delburg, The Netherlands) attached to a Perkin- 
Elmer Series 1 pump and a Perkin-Elmer LC85 
detector. The solvent system was tetrahydrofuran- 
methanol-water-acetic acid (25:30:45:0,1, by vol.) 
which had been brought to pH 5.5 with am- 
monium hydroxide. The aqueous phase contained 
0.1% EDTA to prevent binding of cations to the 
column. Such binding could lead to excessive 
retention of sulfidopeptide leukotrienes [ 181. A 
flow rate of 0.9 ml/min was maintained and the ef- 
fluent was monitored at 280 nm ~eukotrienes) or 
237 nm (monohydroxy acids). Peak areas were 
determined with a Hewlett-Packard 3390 A in- 
tegrator and related to the internal standard PGB2, 
using molar absorption coefficients (M-l ‘cm-‘) of 
28 650 for PGB2 and 40 000 for the leukotrienes at 
280 nm and 29 500 for the monohydroxy acids at 
237 nm [19]. 
3. RESULTS 
Eosinophils and neutrophi~s were purified from 
Table 1 
Leukotriene formation from arachidonic acid by purified human eosinophils and neutrophils: Comparison of data of 
this study with those from the literature 
LTC4 LTD4 LTB4 20- 12epr,6t- 12epi,6t, IS-series LTC4 + LTD4 U-series 
hydroxy- LTB4 + 8c-LTBz, leuko- 
LTB4 6t-LTB4 trienes LTB4 + isomers S-series 
Human 3+ 3 - 29+5 45+8 24*6 3Sl - 0.03 0.00 
neutrophils 
(here)* 





Human 1141’ 1.1 0.7 2.8 n.d. 10.0 n.d. n.d. 0.14 n.d. 
Human (13Jd n.d. n.d. 1.8 n.d. 6.9 5.6 11.8 n.d. 0.82 
Murine [12]’ n.d. n-d. 1.1 n.d. 5.9 7.7 11 2 n d. 0.76 
Horse I1 llf 11.1 1.1 6.5 n.d. 8.9 n.d. n.d. 0.73 n.d. 
a From 5 different granulocyte preparations, eoslnophds and neutrophils have been purrfred and stimulated; mean 
values (expressed as lo6 molecules released/cell) are given f SD 
b The literature data were originally expressed in ng leukotriene formed per 108 cells and were recalculated to lo6 
molecules of leukotriene formed per cell (no corrections have been made for losses during isolation) 
Incubation periods: d*e and here: 5 min; f 15 min; ’ 20 min. c*f Glutathione has not been added; d*e LTC4 was not taken 
into consideration 
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granulocytes obtained from 0.1 to 1.0 1 human 
blood. Fig.1 shows RP-HPLC chromatograms of 
the leukotrienes formed by eosinophils or neutro- 
phils purified from the same granulocyte prepara- 
tion. The absolute quantity of each leukotriene 
produced per cell in 5 min is given in table 1. These 
data prove that almost all LTC4 produced in vitro 
by human granulocytes is synthesized by the 
eosinophil population which accounts only for less 
than 5% of the granulocytes in healthy donors. On 
the other hand, the syntheses of LTB4, 20- 
hydroxy-LTB4 and the two non-enzymically 
formed LTB4 isomers are almost exclusively due to 
the neutrophils. The relative amount of 20- 
hydroxy-LTB4 was found to dependent on the 
length of the incubation period. After 20 min near- 
ly all LTB4 had been converted into 20-hydroxy- 
LTB4. It is interesting to note that even after pro- 
longed incubation of eosinophils 20-hydroxy-LTB4 
could not be detected. 
Both neutrophils and eosinophils produce only 
very small amounts of the double-dioxygenation 
product 12@,6t,8c-LTB4 (sometimes referred to 
as 5S12SDHETE). Furthermore, eosinophils 
were found to produce minor quantities of leuko- 
trienes formed from 15(S)-hydroperoxy-5,8,1 l-cis- 
13-trans-eicosatetraenoic a id (1 SHPETE), which 
were not formed by neutrophils under these condi- 
tions. The small amounts of the latter compounds 
did not allow structural characterization. How- 
ever, it seems reasonable to assume that these 
leukotrienes are formed from lSHPETE, because 
the RP-HPLC chromatogram of the leukotrienes 
produced from 1 SHPETE by porcine lymphocytes 
shows peaks with identical retention times and UV 
spectra (unpublished). The major monohydroxy- 
eicosatetraenoic acid formed by eosinophil& 
was 15-hydroxy-5,8,1 I-cis-l3-&zns-eicosatetra- 
enoic acid (ISHETE, elution time RP-HPLC: 67 
min) whereas neutrophils were found to synthesize 
mainly 5-hydroxy-6-trans-8,11,14-crs-eicosatetra- 
enoic acid (SHETE, elution time RP-HPLC: 92 
min). 
As 5-lipoxygenases have until now always been 
found to be Ca2+-dependent [1,20] whereas 15- 
lipoxygenases have not [21,22], some incubations 
with eosinophils and neutrophils were done in the 
absence of calcium ionophore and of extracellular 
Ca2+. Under these conditions the syntheses of 
LTC4, LTB4 and SHETE were found to be strong- 
ly reduced, whereas the production of 15HETE 
and 15-series leukotrienes by eosinophils was not 
affected significantly. 
Therefore, the effect of Ca2’ supplies additional 
evidence that eosinophilic LTC4 is produced via 
the 5-lipoxygenase pathway. Without added 
glutathione the production of LTC4 by eosinophils 
was reduced to approx. 20% of the amount 
formed in the presence of 5 mM glutathione. 
Therefore, it must be concluded that the eosinophil 
shows its potent and specific capacity to produce 
LTC4 in vitro only when Ca2+, calcium ionophore 
as well as glutathione are present in sufficient 
quantities. 
4. DISCUSSION 
This study demonstrates that human eosino- 
philic and neutrophilic granulocytes ynthesize dif- 
ferent types of leukotrienes. Until now, such a 
specificity for human eosinophils and neutrophils 
has not been reported. It is interesting to compare 
our results with literature data as compiled in table 
1. 
From these data it is obvious that the relative 
amounts of LTB4, its isomers and 15-series leuko- 
trrenes formed by eosinophils have been overesti- 
mated because the production of LTG has not 
been sufficiently stimulated [14] or LTC4 forma- 
tion has not been taken into consideration at all 
[ 12,131. Therefore, these investigations conceal the 
specific potency of the eosinophil to produce large 
amounts of LTC4. 
Our finding that the eosinophilic granulocyte 
population is almost entirely responsible for the 
production of the spasmogenic LTC4 by granulo- 
cytes, may throw new light on the role ofl)the 
eosinophil in (immediate) hypersensitivity reac- 
tions. Frequently, asthmatic patients have high 
numbers of eosinophils in their lung tissue which is 
often reflected in an increased number of blood 
eosinophils. Until now, the role of the eosinophil 
in this disease was often regarded to be beneficial, 
because eosinophils have been shown to contain 
enzymes capable of inactivating LTG [23,24] and 
histamine [25]. However, the here demonstrated 
potency of the eosinophil to produce large 
amounts of LTC4 shows that - under certain con- 
ditions - this activity may prevarl over a possibly 
beneficial activity. 
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